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Leaning Heavily on PET Myocardial Perfusion for Prognosis*
Frank A. Flachskampf, MD,y Vasken Dilsizian, MDz
Uppsala, Sweden; and Baltimore, MarylandThe prevalence of obesity has been steadily
increasing in industrialized nations, reaching nearly
30% of the population (1). Visceral adiposity has
been associated with early and accelerated progres-
sion of atherosclerotic disease (2,3). Beyond playing
an important role in the pathogenesis of metabolic
disorders that ultimately affect the coronary vessels,
obesity is associated with increased risk for
myocardial infarction, heart failure, and decreased
survival, predominantly because of increased car-
diovascular morbidity and mortality (2).See page 278Recent data suggest that plasma proteins origi-
nating from the adipose tissue, such as endo-
cannabinoids, leptin, and adiponectin, play a
central role in the regulation and control of coro-
nary circulatory function in obesity (4). A clinical
study investigating the relationship between body
weight and coronary circulation in subjects without
traditional coronary risk factors showed the pro-
gression of endothelium-dependent coronary vas-
omotion impairment in overweight subjects to
total vasodilatory capacity dysfunction in obese
individuals (3). These ﬁndings imply that obesity
is an independent mediator of coronary artery
disease rather than an epiphenomenon to other
traditional risk factors commonly associated with
obesity, such as diabetes mellitus, hypertension,
dyslipidemia, and insulin resistance (5). Noninva-
sive diagnostic imaging studies that can identify
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contents of this paper to disclose.early in the progression of cardiovascular disease
may help improve patient outcome in such
patients.
Myocardial blood ﬂow assessed at rest and during
stress with positron emission tomographic (PET)
imaging provides a noninvasive surrogate of coro-
nary circulatory function (6). PET myocardial
perfusion imaging uses radionuclides with half-lives
that are considerably shorter than those used in
single-photon emission computed tomography
(SPECT), such as rubidium-82, with a 75-s half-
life, resulting in lower radiation exposure than with
SPECT (7). Moreover, PET images have better
spatial and temporal resolution compared with
SPECT and allow reliable and accurate soft tissue
attenuation correction (8). The latter is particularly
relevant for patients who are obese or have large
body habitus. When combined with tracer kinetic
modeling, PET imaging permits the noninvasive
assessment of the coronary circulatory function in
absolute (ml/min/g) terms (9,10).
In a recent multicenter observational registry,
consisting of more than 7,000 patients with known
or suspected coronary artery disease, the extent and
severity of ischemia and scar as assessed by
rubidium-82 vasodilator PET myocardial perfusion
imaging provided signiﬁcant incremental risk esti-
mates of cardiac death and all-cause mortality
compared with traditional coronary risk factors (11).
The risk-adjusted hazard ratio of cardiac death
increased with each 10% increment in stress myocar-
dial perfusion defect frommild to moderate to severe,
resulting in a nearly 5-fold higher hazard of cardiac
death among patients with severe PET perfusion
defects compared with those with normal PET results
(11). Certainly, there are inherent limitations in such
nonrandomized, observational multicenter registry
studies that use site-speciﬁc protocols on a variety of
PET cameras from different manufacturers, applying
different attenuation correction methods and inter-
pretation algorithms. Demographic information on
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289patients was somewhat limited, because funda-
mental information such as symptom status, left
ventricular ejection fraction, and laboratory values,
such as serum glucose, lipid proﬁle, and renal
function, were missing; hence, classic risk scores
such as the Framingham score or the coronary risk
score of the European Society of Cardiology could
not be calculated. However, the geographic diversity
of the patients, protocols, and cameras may also be
seen as a strength. Such registry data may more
closely reﬂect real-world experience than a tightly
monitored randomized study.
In this issue of iJACC, Chow et al. (12) further
extend the prognostic role of rubidium-82 vasodilator
PETmyocardial perfusion imaging by stratifying the
aforementioned patient population by body mass
index (BMI) and thus providing a look at the per-
formance of PET imaging in a population known to
be difﬁcult to assess by conventional imaging studies.
The detrimental effects of soft tissue attenuation,
which tends to degrade image quality and increase
interpretive errors, have long been recognized with
SPECT (13). Although more recent SPECT cam-
eras include hardware and software solutions for
attenuation correction, they remain nonideal and less
robust than attenuation correction algorithms
applied with PET imaging. Beyond differences in
soft tissue attenuation correction, PET imaging
provides higher myocardial count density at a shorter
image acquisition time than SPECT and less scatter
of activity from adjacent subdiaphragmatic visceral
structures into the myocardial region, allowing a ﬁner
reslicing of the left ventricular myocardium.
As for echocardiography, despite steady im-
provements in transducer technology and increasing
use of left heart contrast, obese patients remain a
challenge for (stress) echocardiographers: “Image
quality is subject to the body habitus of patients, and
ultrasound imaging in general may yet become a
casualty of the obesity epidemic” (14). Obesity also
reduces image quality and/or necessitates higher
radiation doses when applying cardiac computed
tomography (15,16). Cardiac magnetic resonance is
the only imaging technique largely immune to im-
age deterioration due to obesity.
Remarkably, in the study by Chow et al. (12), only
22% of patients had normal BMIs (<25 kg/m2),
underlining the fact that obesity really is the “new
normal.”Another full 22% qualiﬁed as severely obese
(BMI $35 kg/m2). The important ﬁndings of the
study are as follows:
1. Normal PET results conferred a low risk for
cardiac death (<0.5%/year) during the medianfollow-up period of 2.2 years, regardless of
BMI.
2. Added to clinical variables, PET data (the
summed stress score) predicted cardiac or
overall mortality with similar power in all BMI
categories.
3. Within all BMI categories, there was a graded
relation between the extent of stress perfusion
defects on PET imaging and annual cardiac
death rate. This relation held up even in
severely obese patients (BMI $35 kg/m2),
among whom those with the most severe
perfusion defects ($20% of the myocardium)
had an annual cardiac death rate of 4.8%
compared with 0.1% in those with normal
PET results.
4. Added to clinical variables, PET data assigned
patients a more precise risk for future death,
measured by the “net reclassiﬁcation improve-
ment” (NRI), and did so equally well in all BMI
categories.
Reclassiﬁcation of risk is a relatively novel
concept, which determines how many patients are
shifted to more appropriate risk categories after the
evaluation of new disease markers (17,18). In the
present study, reclassiﬁcation was quantiﬁed as
“category-free NRI” (19,20). The category-free
NRI, different from the conventional “categorical”
NRI, does not depend on the number and distri-
bution of levels of cardiovascular risk into which
patients are categorized. Note, however, that the
category-free NRI may be several-fold higher in
absolute value than the conventional “categorical”
NRI (21) and, therefore, cannot be directly
compared with categorical NRIs for diagnostic
markers or procedures reported in the published
research. For example, in the ﬁrst report from the
PET registry (11), PET imaging had a categorical
NRI of 11.6% but a category-free NRI of 54% for
the prediction of cardiac death. In the present study
(12), a category-free NRI of 46% (95% conﬁdence
interval: 31% to 61%) was calculated for the entire
study group for which data on cardiac death were
available, and similar NRIs were calculated across
the different BMI groups.
An interesting aspect of this study is the reap-
pearance of the debated “obesity paradox” (22,23).
In the cohort of subjects studied, overall and cardiac
mortality were lower in patients with higher BMIs.
This of course does not prove that obesity protects
against death. As the investigators point out,
interaction with age (inversely associated with BMI)
as well as with dyspnea symptoms and referral
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may be the reason for this ﬁnding, similar to the
better known “smokers’ paradox.”
The investigators conclude that myocardial
perfusion PET imaging is an attractive option for
risk stratiﬁcation in all patients with suspected or
known coronary artery disease, including those with
increased BMIs. Is PET imaging therefore the next
wave of prognostic testing in the growing popula-
tion of obese patients? Although there is little
doubt that myocardial perfusion PET imaging adds
prognostic power to classic risk factors, there are no
large head-to-head comparisons of the prognostic
power of PET imaging with other tests. In partic-
ular, prognostic comparisons with current stress
echocardiography or cardiac magnetic resonance
imaging are lacking. Furthermore, statistical mea-
sures of predictive power, such as the ones used in
this study (Harrell’s c or the category-free NRI) are
not easy to translate into clinically meaningful in-
formation or to compare between studies. Finally,
as we have learned from new risk markers for cor-
onary artery disease, heart failure, and otherconditions, adding prognostic power is not enough
for a test to be clinically meaningful (24). Rather,
information garnered from a diagnostic test needs
to guide patient management decisions. Ultimately,
such marker-based patient management decisions
should improve patient outcome. This is a formi-
dable threshold to widespread introduction of new
diagnostic techniques, which is similarly faced by
other candidate tests, such as ultrasound measure-
ment of intima-media thickness of the carotid artery
or coronary calcium scoring by computed tomog-
raphy. For PET imaging in particular, availability
and cost further limit its large-scale adoption at this
point. Nonetheless, the study of Chow et al. (12)
shows convincingly that PET imaging is a valid
prognostic instrument to consider for risk assess-
ment of the large and growing group of patients with
obesity.
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